You have 3 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

tofacitinib

Showing 51 - 75 of 258
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Korean Post-marketing Surveillance for Xeljanz XR

Recruiting
  • Active Moderate to Severe Rheumatoid Arthritis
  • Active Ankylosing Spondylitis
  • Tofacitinib XR
  • Seoul, Korea, Republic of
    Pfizer
Oct 10, 2022

Tumors With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic Trial run by the NCI (LMB-100,

Active, not recruiting
Has Results
  • Neoplasms With Mesothelin Expression
  • +3 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 18, 2022

Takayasu Arteritis Trial in Shanghai (Tofacitinib, Methotrexate)

Recruiting
  • Takayasu Arteritis
  • Shanghai, Shanghai, China
    Lindi Jiang
Oct 19, 2021

Rheumatoid Arthritis Trial in Beijing (TLL-018, Tofacitinib)

Recruiting
  • Rheumatoid Arthritis
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Apr 7, 2022

ive Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept

Completed
  • Rheumatoid Arthritis
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 15, 2021

Psoriatic Arthritis, Spondylitis, Sacroilitis Trial in Germany (Tofacitinib 5 MG Oral Tablet [Xeljanz], Placebo oral tablet)

Recruiting
  • Psoriatic Arthritis
  • +2 more
  • Tofacitinib 5 MG Oral Tablet [Xeljanz]
  • Placebo oral tablet
  • Berlin-Steglitz, Germany
  • +18 more
Jul 23, 2022

Tofacitinib Treatment in Rheumatoid Arthritis Patients

Recruiting
  • Rheumatoid Arthritis
    • Athens, Attiki, Greece
    • +18 more
    Jan 4, 2023

    Colitis, Ulcerative, Biologics, Tofacitiniib Trial in Minden

    Terminated
    • Colitis, Ulcerative
    • +6 more
      • Minden, Niedersachsen, Germany
        Gastroenterologische Gemeinschaftspraxis Minden
      Sep 30, 2021

      Rheumatic Arthritis Trial in Germany (Tofacitinib, Etanercept)

      Recruiting
      • Rheumatic Arthritis
      • Tofacitinib
      • Etanercept
      • Berlin, Germany
      • +5 more
      Mar 1, 2022

      Myasthenia Gravis, Generalized Trial in Shanghai (Tofacitinib 5 MG)

      Recruiting
      • Myasthenia Gravis, Generalized
      • Tofacitinib 5 MG
      • Shanghai, China
        Huashan Hospital
      Aug 15, 2021

      ANCA Associated Vasculitis, Drug Use, JAK-STAT Pathway Deregulation Trial in Shanghai (Tofacitinib)

      Completed
      • ANCA Associated Vasculitis
      • +2 more
      • Tofacitinib
      • Shanghai, Shanghai, China
        Department of Rheumatology in Zhongshan hospital, Fudan Universi
      Jul 20, 2021

      Active Ankylosing Spondylitis Trial (VC005 tablets, Tofacitinib Citrate Tablets, VC005 Tablets Placebo)

      Not yet recruiting
      • Active Ankylosing Spondylitis
      • VC005 tablets
      • +2 more
      • (no location specified)
      Apr 4, 2023

      Tofacitinib Special Investigation for Rheumatoid Arthritis

      Completed
      • Rheumatoid Arthritis
      • Tofacitinib (Xeljanz)
      • Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc
      • Tokyo, Japan
        (unnamed)
      Sep 27, 2021

      Rheumatoid Arthritis Trial in Matsumoto ("Baricitinib", "olumiant®", "Biologics", Tofacitinib 5 MG [Xeljanz])

      Recruiting
      • Rheumatoid Arthritis
      • "Baricitinib", "olumiant®"
      • +2 more
      • Matsumoto, Nagano, Japan
        Yukio Nakamura
      Sep 20, 2021

      Granulomatosis With Polyangiitis Trial in Shanghai (Tofacitinib, Methotrexate)

      Recruiting
      • Granulomatosis With Polyangiitis
      • Shanghai, Shanghai, China
        Department of Rheumatology in Zhongshan hospital, Fudan Universi
      Jul 5, 2021

      Cutaneous Sarcoidosis, Granuloma Annulare Trial in New Haven (Tofacitinib 5 mg twice daily)

      Completed
      • Cutaneous Sarcoidosis
      • Granuloma Annulare
      • Tofacitinib 5 mg twice daily
      • New Haven, Connecticut
        Yale Center for Clinical Investigation
      Jul 13, 2021

      Rheumatoid Arthritis Trial in Bordeaux, Limoges (Clinical examination, Pain assessment, blood sample)

      Recruiting
      • Rheumatoid Arthritis
      • Clinical examination
      • +3 more
      • Bordeaux, France
      • +1 more
      Nov 9, 2021

      Rheumatoid Arthritis Trial (GS-5718, Placebo to match GS-5718, Tofacitinib 5 mg)

      Withdrawn
      • Rheumatoid Arthritis
      • (no location specified)
      May 11, 2022

      Ulcerative Colitis Acute Trial in Hamilton (Tofacitinib 10 MG [Xeljanz])

      Recruiting
      • Ulcerative Colitis Acute
      • Tofacitinib 10 MG [Xeljanz]
      • Hamilton, Ontario, Canada
        McMaster University
      Jun 8, 2021

      Rheumatoid Arthritis Trial in Hangzhou (Tofacitinib)

      Recruiting
      • Rheumatoid Arthritis
      • Tofacitinib
      • Hangzhou, Zhejiang, China
        2nd Affiliated Hospital, School of Medicine, Zhejiang University
      Jun 9, 2021

      Depression After First-year of Tofacitinib in RA Patients

      Recruiting
      • Rheumatoid Arthritis
        • Prague, Czech Republic, Czechia
        • +7 more
        Nov 18, 2021

        Idiopathic Inflammatory Myopathies Trial in Beijing (tofacitinib)

        Recruiting
        • Idiopathic Inflammatory Myopathies
        • tofacitinib
        • Beijing, Beijing, China
          Department of Rheumatology and Immunology, Peking University Peo
        Oct 9, 2022

        Inpatient COVID-19 Treatments

        Active, not recruiting
        • COVID-19
        • Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI)
        • New York, New York
          Aetion, Inc.
        Jan 12, 2023

        Arthritis, Rheumatoid Trial in Jinan (Iguratimod, Tofacitinib, Pred)

        Recruiting
        • Arthritis, Rheumatoid
        • Jinan, Shandong, China
          Qilu Hospital
        Jun 17, 2021

        Granuloma Annulare Trial in New Haven (AC-1101)

        Recruiting
        • Granuloma Annulare
        • New Haven, Connecticut
          Yale Center for Clinical Investigation
        Nov 2, 2022